AbbVie Inc. $ABBV Shares Acquired by Modera Wealth Management LLC

Modera Wealth Management LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 9.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 85,867 shares of the company’s stock after purchasing an additional 7,590 shares during the quarter. Modera Wealth Management LLC’s holdings in AbbVie were worth $22,462,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABBV. State Street Corp raised its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after buying an additional 106,091 shares during the period. Legal & General Group Plc acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $2,905,952,000. Deutsche Bank AG increased its position in AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Finally, Amundi increased its position in AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after buying an additional 247,689 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 1.4%

Shares of ABBV opened at $294.80 on Friday. The company has a market capitalization of $520.85 billion, a price-to-earnings ratio of 83.28, a PEG ratio of 1.33 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74. The stock has a 50 day moving average of $269.35 and a 200 day moving average of $237.23.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.86 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ABBV. Barclays upped their price target on AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 21st. BNP Paribas Exane raised their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Oppenheimer increased their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.